Healthcare organisations are adopting AI across clinical decision support, remote monitoring, documentation, administration, analytics and security, increasing reliance on external vendors and complex supply chains. These tools can create limited visibility into vendor security, data governance, model integrity, subcontractors, offshore development and open-source assets. An April 2026 guide from the Health Sector Coordinating Council Cybersecurity Working Group sets out practices for managing third-party AI risk across procurement, contracting, implementation, monitoring, incident response and end-of-life planning. It frames AI governance as a lifecycle process for organisations of different sizes and maturity levels.
Visibility Starts Before Procurement
Third-party AI risk management begins before vendor evaluation. Healthcare organisations need to determine whether AI is the appropriate solution for a defined problem or opportunity, rather than adopting AI for innovation alone. A structured use case assessment documents the intended clinical or operational purpose, expected workflows, integration points, user populations, frequency of use and criticality to patient care or business operations.
Risk classification is central to that early assessment. AI tools may have low, medium, high or critical impact depending on their safety, financial and operational consequences. Low-impact tools include applications where failure would not affect patient care or significant financial outcomes. Medium-impact systems support decision-making while humans retain full control. High-impact systems can substantially influence important clinical or financial decisions. Critical systems may affect patient life, safety or organisation-wide operations.
Data sensitivity also shapes the risk profile. AI solutions may process protected health information, personally identifiable information or other sensitive data. Organisations need to identify model type, automation level, human oversight, hosting arrangements, training location, regulatory classification and controls for data protection, model integrity and compliance.
Vendor evaluation then extends beyond standard third-party risk management. Traditional checks on financial stability, cybersecurity practices, data residency, privacy compliance, insurance and business continuity remain necessary. AI procurement also requires scrutiny of training data, data lineage, bias mitigation, model transparency, decision thresholds, human override, model versioning, open-source components, cloud service relationships and fourth-party suppliers.
Contracts and Deployment Need AI-Specific Controls
Standard software contracts and business associate agreements are not sufficient for AI systems in healthcare. AI solutions can change through model updates, experience drift as data distributions evolve and behave unpredictably in production environments. Contract terms therefore need to define shared responsibility for governance, risk management, security, compliance and quality assurance.
Data ownership and permitted use require particular attention. Healthcare organisations retain ownership of input data, output data and derived insights. Vendor use of organisational data for model training, testing or improvement requires explicit written consent. Contracts also need to distinguish training data from operational data, define rights over model improvements and restrict reuse of proprietary data or protected health information across other clients without authorisation.
AI-specific clauses need to cover security controls, audit rights, update management, testing support, rollback procedures, performance thresholds, model drift monitoring, bias monitoring, transparency and incident response. Vendors need to disclose third-party models, application programming interfaces, data sources and subcontractors where relevant. Contracts also need requirements for notification of changes to model architecture, training data or external dependencies.
Must Read: Cybersecurity Risks Escalate Across Healthcare Systems
Implementation introduces another high-risk period. AI systems need testing in sandbox or staging environments before production use. Integration with electronic health records, clinical systems and other interfaces needs validation, along with data flows, access permissions, audit logging, encryption, vulnerability management and role-based access.
AI-specific testing extends beyond conventional application security. Threat modelling needs to address prompt injection, data poisoning, adversarial input, model manipulation, excessive agency, sensitive information disclosure, vector and embedding weaknesses, system prompt leakage, misinformation and unbounded consumption. For autonomous or semi-autonomous agents, organisations need unique identities, defined permissions, credential controls, behavioural baselines and monitoring for deviation from expected activity.
Monitoring and Recovery Extend Governance Across the Lifecycle
After deployment, AI systems require more intensive oversight than traditional software. Model performance can drift, bias can emerge across different populations and vendor updates can alter functionality, algorithms or configurations. Security settings may reset during updates, while new attack patterns can affect systems that were previously validated.
Performance monitoring needs to track measures relevant to each use case, including accuracy, false positives, false negatives, user overrides, confidence scores, system responsiveness, user adoption and real-world performance against validation benchmarks. Model drift detection requires attention to changes in input data, changing relationships between inputs and outputs and thresholds for acceptable variation.
Security and compliance monitoring also need to continue throughout the operational lifecycle. Access logs, authentication events, vulnerabilities, unusual behaviour, configuration changes and AI-specific attack patterns require regular review. Compliance activities include periodic audits against contractual requirements, validation of business associate agreements, protected health information handling, consent and disclosure practices and applicable regulatory requirements.
Vendor performance management remains part of governance after go-live. Healthcare organisations need to track service levels, document non-compliance, hold regular performance reviews, coordinate on planned updates and discuss emerging risks. Vendor updates require review, testing in non-production environments, verification of security settings, validation of model performance and approval through change management before production deployment.
Incident response also needs AI-specific preparation. AI failures may involve model degradation, bias events, data poisoning, adversarial attacks, hallucinations, privacy breaches or compromised training data. Response planning needs severity levels, escalation criteria, vendor coordination, forensic procedures, safe-mode options, rollback processes, revalidation and regulatory notification where required.
Third-party AI risk management in healthcare depends on lifecycle discipline rather than one-time procurement checks. Effective governance starts with use case justification, risk classification and vendor due diligence, then continues through AI-specific contracting, implementation testing, user training, monitoring, incident response and end-of-life planning. The central operational challenge is transparency across layered AI supply chains, including subcontractors, open-source assets, cloud services and model dependencies. Healthcare organisations need scalable processes that match organisational size, AI maturity and the impact of each system on patient safety, operations, data protection and resilience.
Source: Health Sector Coordinating Council. Cybersecurity Working Group
Image Credit: iStock
